glp-1 and breast cancer risk Study links drugs to lower diagnosis rates GLP-1s in Oncology: Nursing Insights

In particular, GLP-1 RAs, beyond their potent glucose-lowering effects, promote substantial weight loss by delaying gastric emptying and suppressing appetite through both the peripheral nervous system (PNS) and central nervous system (CNS)

To investigate this, ex vivo assessment of thoracic aorta sections from vehicle- and semaglutide-treated ZSF1 obese rats was performed

[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions

it just comes down to which one will work best for you and your lifestyle and needs

Eli Lilly is also developing a drug called retatrutide, that targets three receptors (glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors)

NotCos AI technology allowed the company to rapidly iterate millions of possible formulations, optimizing the desired outcomes to reach a final formulation